Nonalcoholic Steatohepatitis Therapeutics Market

Nonalcoholic Steatohepatitis Therapeutics
Market - Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast 2015 -
2025
According to a new market report published by Transparency
Market Research “Nonalcoholic Steatohepatitis Therapeutics
Market - Global Industry Analysis, Size, Share, Growth, Trends,
and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis
(NASH) therapeutics market is anticipated to expand at a CAGR
of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
The cause of NASH is yet unclear, though research is ongoing in
an attempt to find effective treatments. At present, treatment of
NASH focuses on regulating some of the medical conditions
associated with it such as diabetes and obesity and monitoring
for advancement.
As with nonalcoholic fatty liver disease, people with NASH
should be vaccinated against hepatitis A and B if they are not
already immune. Diagnosis of NASH is often done with routine
laboratory tests. Further tests help confirm the presence of
NASH and exclude other types of liver disease. Imaging tests
such as ultrasound, CT scan, or magnetic resonance imaging
[MRI] may expose fat accumulation in the liver but cannot

differentiate NASH from other causes of liver disease that have
a similar appearance.
Nonalcoholic fatty liver disease (NAFLD) is a disorder
categorized by excess fat in the liver of people who drink little
to no alcohol. No direct cause has yet been identified, however
obesity and insulin resistance are believed to have major roles.
Most often, NAFLD goes relatively undetected, as a liver can
remain fatty without obstructing its function. Though, NAFLD
can progress into a far more severe condition known as
nonalcoholic steatohepatitis (NASH), a disease characterized by
inflammation and irreversible cell death.
Browse Full Research Report on Nonalcoholic
Steatohepatitis Therapeutics Market:
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html
NASH is a disease that advances over time. Over a period of ten
years up to 20% of patients with NASH develop cirrhosis of the
liver, and 10% die from the disease. At present, NASH is one of
the leading causes of liver transplants in the U.S., with a
considerable proportion of the general population currently
suffering from the disease.
NAFLD and NASH are both closely related to diabetes and
obesity, and together are now considered as the leading cause of

liver disease in Western countries. Thus, there is an urgent need
for effective treatment options for these diseases. The need for
treatment is expected to propel the growth of NASH
therapeutics in coming years.
The NASH market is segmented based on drug type which
includes potential phase III candidates such as Obeticholic acid
(OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the
report provides a list of the candidates in Phase I and Phase II
clinical trials. Based on the drug type, Elafibranor is expected to
account for a major share of this market followed by Obeticholic
Acid (OCA) market and the market for Elafibranor is expected
to grow at the highest CAGR.
The market overview section of the report demonstrates major
market dynamics such as drivers, restraints, and opportunities
that influence the current and future status of the industry. The
market overview section includes epidemiology of Nonalcoholic
steatohepatitis (NASH) by region, to provide a thorough
analysis of the overall addressable global market for the NASH
therapeutics. Moreover, the report provides qualitative
information about diagnosis and treatment of NASH.

The report also provides important recommendations for market
players and new entrants. These recommendations would enable
existing market players to expand their market shares and help
new companies to establish their presence in the NASH market
across different regions worldwide. The report concludes with
the company profiles section, which includes key information
about major players in the market such as financial overview,
business strategies, and recent developments.
Major players in this market are Astazeneca Plc (U.K.), Intercept
Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd.
(Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.),
Zydus Cadila (India), Immuron Ltd. (Australia), Conatus
Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).
Browse Full Press Release on Nonalcoholic Steatohepatitis
Therapeutics Market:
Press Release
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of

analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com